Drugs / NNC9204-0530
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02870231 | Aug 2016 → Sep 2017 | metabolic disease, obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02835235 | Jul 2016 → Jul 2017 | metabolic disease, obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02235961 | Sep 2014 → Jul 2016 | metabolic disease, obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NNC9204-0530 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02870231 ↗ |
| Route | Subcutaneous | “Administered as single subcutaneous (s.c., under the skin) injections.” NCT02235961 ↗ |